Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial
Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial
Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial
Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial
Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial
Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…
